Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.23.3
Stock-Based Compensation
9 Months Ended
Sep. 30, 2023
Stock-Based Compensation  
Stock-Based Compensation

7.  Stock-Based Compensation

As of September 30, 2023, an aggregate of 366,924 shares of common stock were authorized under the Company’s 2019 Stock Incentive Plan (the “2019 Plan”), subject to an “evergreen” provision that will automatically increase the maximum number of shares of common stock that may be issued under the term of the 2019 Plan. As of September 30, 2023, 155,994 shares of common stock were available for future grants under the 2019 Plan. As of September 30, 2023, an aggregate of 14,584 shares of common stock were authorized under the Company’s 2016 Consolidated Stock Incentive Plan (the “2016 Plan”) and 13,334 shares of common stock were available for future grants under the 2016 Plan.

The Company recorded stock-based compensation expense (benefit) in the following expense categories of its unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022:

    

Three Months Ended September 30, 

Nine Months Ended September 30, 

2023

    

2022

2023

    

2022

General and administrative

$

(178,915)

$

428,571

$

302,817

$

1,490,667

Research and development

 

(113,428)

 

82,041

 

(33,459)

 

613,818

Total

$

(292,343)

$

510,612

$

269,358

$

2,104,485

Stock-based compensation expense for the three and nine months ended September 30, 2023 includes the reversal of expense previously recognized of $0.4 million for unvested stock options that were forfeited during the period in connection with the Company’s restructuring, see Note 8.

Stock Options

Below is a table summarizing the options issued and outstanding as of and for the nine months ended September 30, 2023:

Weighted-

Weighted-

Average

Average

Total

    

Exercise

Remaining

Aggregate

Price Per

Contractual

Intrinsic

    

Stock Options

    

Share

    

Life (in years)

    

Value

Outstanding at December 31, 2022

365,287

$

53.27

Granted

1,875

4.34

Exercised

(125,984)

0.02

Forfeited

(44,693)

66.51

Outstanding at September 30, 2023

196,485

83.93

4.81

$

Exercisable as of September 30, 2023

151,137

$

93.71

3.82

$

As of September 30, 2023, unrecognized compensation costs associated with the stock options of $0.6 million will be recognized over an estimated weighted average amortization period of 3.62 years.

The intrinsic value of options exercised during the nine months ended September 30, 2023 and 2022 was $0.3 million and $0.3 million, respectively.

The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 and 2022 was $3.21 and $23.31, respectively.

Key assumptions used to estimate the fair value of the stock options granted during the nine months ended September 30, 2023 and 2022 included:

Nine Months Ended September 30, 

2023

    

2022

Expected term of options (years)

5.4 - 6.1

5.3 - 6.1

Expected common stock price volatility

82.3% - 85.2%

73.7% - 78.5%

Risk-free interest rate

3.5% - 4.0%

1.4% - 3.4%

Expected dividend yield

Restricted Stock Units

Below is a table summarizing the restricted stock units granted and outstanding as of and for the nine months ended September 30, 2023:

Weighted-

Average Grant

Restricted Stock 

Date Fair Value 

    

Units

    

Price

Unvested as of December 31, 2022

 

$

Granted

19,823

4.00

Forfeited

 

(8,713)

 

Unvested as of September 30, 2023

 

11,110

 

4.00

Total unrecognized expense remaining

$

30,208

 

  

Weighted-average years expected to be recognized over

 

3.4